Zydus Lifesciences
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
Zydus Lifesciences is navigating a strategic transformation towards a higher-margin, innovation-led portfolio, as highlighted by management's focus on specialty products and biosimilars. The recent acquisition of Assertio Holdings is expected to enhance its presence in the US oncology market, while the launch of new products like Saroglitazar aims to offset revenue declines from legacy generics. However, the company faces near-term margin pressures due to elevated R&D and integration costs. Vista's financial outlook reflects moderating revenue growth and ongoing margin challenges, with a target price of approximately INR 940. Despite a robust pipeline and a disciplined capital allocation strategy, the competitive landscape and regulatory hurdles present significant risks. Over the next 12-24 months, Zydus must successfully commercialize its innovative assets and manage cost pressures to achieve its long-term growth objectives. Key opportunities include expanding its specialty portfolio and leveraging favorable currency movements, while headwinds consist of rising input costs, increased competition, and potential regulatory delays
Why We Like This Stock
- Strategic pivot towards high-margin specialty products and biosimilars enhances growth potential
- Successful integration of Assertio Holdings is expected to strengthen Zydus's position in the US oncology market
- Robust pipeline of innovative products supports long-term revenue growth
Things To Watch Out For
- Near-term margin pressures due to high R&D and acquisition-related costs may impact profitability
- Increased competition in the US market could constrain pricing power and revenue growth
- Regulatory challenges and execution risks associated with new product launches may hinder performance
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 19,547 | 23,242 | 27,148 | 28,231 | 31,698 |
| Profit Before Tax (Cr.) | 4,810 | 6,212 | 7,138 | 4,676 | 5,901 |
| PBT Margin | 24.6% | 26.7% | 26.3% | 16.6% | 18.6% |
| Net Profit (Cr.) | 3,459 | 4,158 | 5,731 | 3,702 | 4,671 |
| Earnings Per Share | 34.7 | 41.7 | 57.4 | 37.1 | 46.8 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| HSBC | ► Hold | 1,100 | 01-Oct-2026 |
| Bernstein | ▲ Buy | 1,457 | 18-Sep-2026 |
| Macguire | ▲ Outperform | 1,285 | 27-Aug-2026 |
| Axis Securities | ▲ Buy | 1,250 | 12-Aug-2026 |
| CLSA | ▲ Outperform | 1,310 | 12-Aug-2026 |
| Citigroup | ▼ Sell | 1,040 | 12-Aug-2026 |
| Deven Choksey | ► Hold | 1,255 | 12-Aug-2026 |
| ICICI Securities | ▼ Sell | 1,050 | 12-Aug-2026 |
| Investec | ▼ Sell | 1,090 | 12-Aug-2026 |
| JPMorgan | ► Hold | 1,240 | 12-Aug-2026 |
| Jeffries | ▲ Buy | 1,370 | 12-Aug-2026 |
| Moneycontrol | ▲ Overweight | nan | 12-Aug-2026 |
| Motilal Oswal | ► Neutral | 1,125 | 12-Aug-2026 |
| Nuvama | ▲ Buy | 1,400 | 12-Aug-2026 |
| Prabhudas Liladhar | ► Accumulate | 1,200 | 12-Aug-2026 |
| Elara Capital | ▲ Buy | 1,311 | 25-May-2026 |
| Choice Equity | ► Hold | 1,120 | 20-May-2026 |
| HDFC Securities | ► Add | 1,140 | 20-May-2026 |
| Nomura | ▲ Buy | 1,180 | 19-May-2026 |
Company Overview
Show Company Profile
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Consumer Products, and Medical Technologies. The company offers active pharmaceutical ingredients, human and finished dosage formulations, generics, branded generics, specialty formulations, biosimilars, vaccines, novel therapeutics, medical devices and technologies, consumer wellness, veterinary, and animal health products. It also provides biological products in the areas of oncology, autoimmune disorders, nephrology, inflammation, rheumatology, hepatology, and infectious diseases; and designs and executes clinical trials across new chemical entities (NCEs), biologics, vaccines, and specialty generics. In addition, the company operates seasonal, skin and healthcare, and food and nutrition products under the Glucon D, Complan, Sugar Free, Nycil, Everyuth, Nutralite, and RiteBite Max Protein brands. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India. Zydus Lifesciences Limited is a subsidiary of Zydus Family Trust.